Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

[Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha].

Drózdz W, Ziółkowska-Kochan M, Kozielewicz D, Dybowska D, Borkowska A, Halota W.

Przegl Epidemiol. 2008;62(1):93-100. Polish.

PMID:
18536230
2.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
3.

[Cognitive disturbances observed in chronic hepatitis C patients during pegylated interferon alpha and ribavirin therapy].

Pawełczyk T, Pawełczyk A, Białkowska J, Jabłkowski M, Strzelecki D, Dworniak D, Rabe-Jabłońska J.

Psychiatr Pol. 2008 Nov-Dec;42(6):925-41. Polish.

PMID:
19441669
4.

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.

J Viral Hepat. 2005 May;12(3):292-9.

PMID:
15850470
5.

Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

Nudo CG, Wong P, Hilzenrat N, Deschênes M.

Can J Gastroenterol. 2006 Sep;20(9):589-92.

7.

Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.

Chaudhari S, Park J, Anand BS, Pimstone NR, Dieterich DT, Batash S, Bini EJ.

Dig Dis Sci. 2004 Jun;49(6):1000-6.

PMID:
15309891
8.
9.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
10.

Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.

Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Słuzewski W.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1095-103.

PMID:
17724740
11.

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.

August-Jörg BS, Borovicka J, Dufour JF, Gonvers JJ, Henz S, Hermann R, Meyenberger C, Weitz M, Renner EL; Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2003 Aug 23;133(33-34):455-60.

PMID:
14625812
12.
13.

Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.

Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Antivir Ther. 2007;12(8):1225-35.

PMID:
18240862
14.

Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.

Pavlović Z, Delić D, Marić NP, Vuković O, Jašović-Gašić M.

Psychiatr Danub. 2011 Dec;23(4):370-7.

15.

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, Jessen H, Weitner L, Mutz A, Schranz D, Rockstroh JK; Kaad Study Group.

J Infect. 2006 Jul;53(1):36-42. Epub 2005 Nov 2.

PMID:
16269184
16.

[Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].

Adamek A, Adamek J, Juszczyk J.

Pol Merkur Lekarski. 2004 Nov;17(101):443-5. Polish.

PMID:
15754628
17.

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.

Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB.

Am J Gastroenterol. 2008 May;103(5):1131-5. doi: 10.1111/j.1572-0241.2008.01793.x.

PMID:
18477343
18.
19.

[Haematologic adverse effects of treatment of chronic viral hepatitis B and C].

Porubcin S, Schréter I, Kristian P, Pellová A.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):74-8. Slovak.

PMID:
18756437
20.

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT.

Clin Transplant. 2004 Apr;18(2):166-73.

PMID:
15016131

Supplemental Content

Support Center